Loading…
Improvement of impaired albumin binding capacity in acute‐on‐chronic liver failure by albumin dialysis
Extracorporeal albumin dialysis (ECAD) enables the elimination of albumin bound substances and is used as artificial liver support system. Albumin binding function for the benzodiazepine binding site specific marker Dansylsarcosine was estimated in plasma samples of 22 patients with cirrhosis and hy...
Saved in:
| Published in: | Liver transplantation 2008-09, Vol.14 (9), p.1333-1339 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3854-9830757422467986a4adfa60093d81ab62d997b21dcb1f8b724bf2fb9547eb243 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3854-9830757422467986a4adfa60093d81ab62d997b21dcb1f8b724bf2fb9547eb243 |
| container_end_page | 1339 |
| container_issue | 9 |
| container_start_page | 1333 |
| container_title | Liver transplantation |
| container_volume | 14 |
| creator | Klammt, Sebastian Mitzner, Steffen R. Stange, Jan Loock, Jan Heemann, Uwe Emmrich, Jörg Reisinger, Emil C. Schmidt, Reinhard |
| description | Extracorporeal albumin dialysis (ECAD) enables the elimination of albumin bound substances and is used as artificial liver support system. Albumin binding function for the benzodiazepine binding site specific marker Dansylsarcosine was estimated in plasma samples of 22 patients with cirrhosis and hyperbilirubinaemia (ECAD: n = 12; control: n = 10) during a period of 30 days in a randomized controlled clinical ECAD trial. Albumin Binding Capacity (ABiC) at baseline was reduced to 31.8% (median; range 24%‐74%) and correlated to the severity of liver disease. Within two weeks a significant improvement of ABiC and a reduction of the albumin bound markers bilirubin and bile acids were observed in the ECAD group. During single treatments a significant decrease of albumin bound substances (bilirubin and bile acids) as well as an increase in ABiC was observed. In the control group, baseline ABiC was significantly lower in patients who died during study period (34.2% vs. 41.7%; P < 0.028), whereas no significant differences were observed for CHILD, coagulation factors, albumin, bile acids nor bilirubin. At baseline 13 patients had a severely impaired ABiC ( |
| doi_str_mv | 10.1002/lt.21504 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69496587</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69496587</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3854-9830757422467986a4adfa60093d81ab62d997b21dcb1f8b724bf2fb9547eb243</originalsourceid><addsrcrecordid>eNp1kMtKxDAUhoMozngBn0CyEjcdkzSXZimDl4EBN-O6JGmqGdJ2TNqR7nwEn9EnsdphXLk55_Dz8cH5AbjAaIYRIje-nRHMED0AU8yISDgV6eH-5mwCTmJcI4Qxk-gYTHAm2MDgKVgvqk1otraydQubErpqo1ywBVRed5WroXZ14eoXaNRGGdf2cMiU6Vr79fHZ1MMwr6GpnYHebW2ApXK-Cxbqfm8onPJ9dPEMHJXKR3u-26fg-f5uNX9Mlk8Pi_ntMjFpxmgisxQJJighlAuZcUVVUSqOkEyLDCvNSSGl0AQXRuMy04JQXZJSS0aF1YSmp-Bq9A6PvXU2tnnlorHeq9o2Xcy5pJKzTAzg9Qia0MQYbJlvgqtU6HOM8p9ec9_mv70O6OXO2enKFn_grsgBSEbg3Xnb_yvKl6tR-A0GZYPA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69496587</pqid></control><display><type>article</type><title>Improvement of impaired albumin binding capacity in acute‐on‐chronic liver failure by albumin dialysis</title><source>Wiley Online Library</source><creator>Klammt, Sebastian ; Mitzner, Steffen R. ; Stange, Jan ; Loock, Jan ; Heemann, Uwe ; Emmrich, Jörg ; Reisinger, Emil C. ; Schmidt, Reinhard</creator><creatorcontrib>Klammt, Sebastian ; Mitzner, Steffen R. ; Stange, Jan ; Loock, Jan ; Heemann, Uwe ; Emmrich, Jörg ; Reisinger, Emil C. ; Schmidt, Reinhard</creatorcontrib><description>Extracorporeal albumin dialysis (ECAD) enables the elimination of albumin bound substances and is used as artificial liver support system. Albumin binding function for the benzodiazepine binding site specific marker Dansylsarcosine was estimated in plasma samples of 22 patients with cirrhosis and hyperbilirubinaemia (ECAD: n = 12; control: n = 10) during a period of 30 days in a randomized controlled clinical ECAD trial. Albumin Binding Capacity (ABiC) at baseline was reduced to 31.8% (median; range 24%‐74%) and correlated to the severity of liver disease. Within two weeks a significant improvement of ABiC and a reduction of the albumin bound markers bilirubin and bile acids were observed in the ECAD group. During single treatments a significant decrease of albumin bound substances (bilirubin and bile acids) as well as an increase in ABiC was observed. In the control group, baseline ABiC was significantly lower in patients who died during study period (34.2% vs. 41.7%; P < 0.028), whereas no significant differences were observed for CHILD, coagulation factors, albumin, bile acids nor bilirubin. At baseline 13 patients had a severely impaired ABiC (<40%), improvement of ABiC was more frequent in the ECAD group (5/6) than in the SMT group (2/7). Reduced albumin binding function is present in decompensated liver failure and is related to severity and 30 day survival. ABiC can be improved by ECAD. The beneficial effect of this treatment may be related to the improvement of albumin binding function more than to the elimination of specific substances. Characterization of albumin function by the ABiC test may help to evaluate different liver support systems and other therapeutic measures. Liver Transpl 14:1333–1339,2008. © 2008 AASLD.</description><identifier>ISSN: 1527-6465</identifier><identifier>EISSN: 1527-6473</identifier><identifier>DOI: 10.1002/lt.21504</identifier><identifier>PMID: 18756471</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Albumins - chemistry ; Albumins - metabolism ; Benzodiazepines - chemistry ; Bile Acids and Salts - chemistry ; Bilirubin - chemistry ; Binding Sites ; Dansyl Compounds - chemistry ; Dialysis - methods ; Female ; Fibrosis - metabolism ; Humans ; Liver Failure - therapy ; Male ; Middle Aged ; Sarcosine - analogs & derivatives ; Sarcosine - chemistry ; Treatment Outcome</subject><ispartof>Liver transplantation, 2008-09, Vol.14 (9), p.1333-1339</ispartof><rights>Copyright © 2008 American Association for the Study of Liver Diseases</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3854-9830757422467986a4adfa60093d81ab62d997b21dcb1f8b724bf2fb9547eb243</citedby><cites>FETCH-LOGICAL-c3854-9830757422467986a4adfa60093d81ab62d997b21dcb1f8b724bf2fb9547eb243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Flt.21504$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Flt.21504$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18756471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Klammt, Sebastian</creatorcontrib><creatorcontrib>Mitzner, Steffen R.</creatorcontrib><creatorcontrib>Stange, Jan</creatorcontrib><creatorcontrib>Loock, Jan</creatorcontrib><creatorcontrib>Heemann, Uwe</creatorcontrib><creatorcontrib>Emmrich, Jörg</creatorcontrib><creatorcontrib>Reisinger, Emil C.</creatorcontrib><creatorcontrib>Schmidt, Reinhard</creatorcontrib><title>Improvement of impaired albumin binding capacity in acute‐on‐chronic liver failure by albumin dialysis</title><title>Liver transplantation</title><addtitle>Liver Transpl</addtitle><description>Extracorporeal albumin dialysis (ECAD) enables the elimination of albumin bound substances and is used as artificial liver support system. Albumin binding function for the benzodiazepine binding site specific marker Dansylsarcosine was estimated in plasma samples of 22 patients with cirrhosis and hyperbilirubinaemia (ECAD: n = 12; control: n = 10) during a period of 30 days in a randomized controlled clinical ECAD trial. Albumin Binding Capacity (ABiC) at baseline was reduced to 31.8% (median; range 24%‐74%) and correlated to the severity of liver disease. Within two weeks a significant improvement of ABiC and a reduction of the albumin bound markers bilirubin and bile acids were observed in the ECAD group. During single treatments a significant decrease of albumin bound substances (bilirubin and bile acids) as well as an increase in ABiC was observed. In the control group, baseline ABiC was significantly lower in patients who died during study period (34.2% vs. 41.7%; P < 0.028), whereas no significant differences were observed for CHILD, coagulation factors, albumin, bile acids nor bilirubin. At baseline 13 patients had a severely impaired ABiC (<40%), improvement of ABiC was more frequent in the ECAD group (5/6) than in the SMT group (2/7). Reduced albumin binding function is present in decompensated liver failure and is related to severity and 30 day survival. ABiC can be improved by ECAD. The beneficial effect of this treatment may be related to the improvement of albumin binding function more than to the elimination of specific substances. Characterization of albumin function by the ABiC test may help to evaluate different liver support systems and other therapeutic measures. Liver Transpl 14:1333–1339,2008. © 2008 AASLD.</description><subject>Adult</subject><subject>Albumins - chemistry</subject><subject>Albumins - metabolism</subject><subject>Benzodiazepines - chemistry</subject><subject>Bile Acids and Salts - chemistry</subject><subject>Bilirubin - chemistry</subject><subject>Binding Sites</subject><subject>Dansyl Compounds - chemistry</subject><subject>Dialysis - methods</subject><subject>Female</subject><subject>Fibrosis - metabolism</subject><subject>Humans</subject><subject>Liver Failure - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Sarcosine - analogs & derivatives</subject><subject>Sarcosine - chemistry</subject><subject>Treatment Outcome</subject><issn>1527-6465</issn><issn>1527-6473</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp1kMtKxDAUhoMozngBn0CyEjcdkzSXZimDl4EBN-O6JGmqGdJ2TNqR7nwEn9EnsdphXLk55_Dz8cH5AbjAaIYRIje-nRHMED0AU8yISDgV6eH-5mwCTmJcI4Qxk-gYTHAm2MDgKVgvqk1otraydQubErpqo1ywBVRed5WroXZ14eoXaNRGGdf2cMiU6Vr79fHZ1MMwr6GpnYHebW2ApXK-Cxbqfm8onPJ9dPEMHJXKR3u-26fg-f5uNX9Mlk8Pi_ntMjFpxmgisxQJJighlAuZcUVVUSqOkEyLDCvNSSGl0AQXRuMy04JQXZJSS0aF1YSmp-Bq9A6PvXU2tnnlorHeq9o2Xcy5pJKzTAzg9Qia0MQYbJlvgqtU6HOM8p9ec9_mv70O6OXO2enKFn_grsgBSEbg3Xnb_yvKl6tR-A0GZYPA</recordid><startdate>200809</startdate><enddate>200809</enddate><creator>Klammt, Sebastian</creator><creator>Mitzner, Steffen R.</creator><creator>Stange, Jan</creator><creator>Loock, Jan</creator><creator>Heemann, Uwe</creator><creator>Emmrich, Jörg</creator><creator>Reisinger, Emil C.</creator><creator>Schmidt, Reinhard</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200809</creationdate><title>Improvement of impaired albumin binding capacity in acute‐on‐chronic liver failure by albumin dialysis</title><author>Klammt, Sebastian ; Mitzner, Steffen R. ; Stange, Jan ; Loock, Jan ; Heemann, Uwe ; Emmrich, Jörg ; Reisinger, Emil C. ; Schmidt, Reinhard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3854-9830757422467986a4adfa60093d81ab62d997b21dcb1f8b724bf2fb9547eb243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Albumins - chemistry</topic><topic>Albumins - metabolism</topic><topic>Benzodiazepines - chemistry</topic><topic>Bile Acids and Salts - chemistry</topic><topic>Bilirubin - chemistry</topic><topic>Binding Sites</topic><topic>Dansyl Compounds - chemistry</topic><topic>Dialysis - methods</topic><topic>Female</topic><topic>Fibrosis - metabolism</topic><topic>Humans</topic><topic>Liver Failure - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Sarcosine - analogs & derivatives</topic><topic>Sarcosine - chemistry</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klammt, Sebastian</creatorcontrib><creatorcontrib>Mitzner, Steffen R.</creatorcontrib><creatorcontrib>Stange, Jan</creatorcontrib><creatorcontrib>Loock, Jan</creatorcontrib><creatorcontrib>Heemann, Uwe</creatorcontrib><creatorcontrib>Emmrich, Jörg</creatorcontrib><creatorcontrib>Reisinger, Emil C.</creatorcontrib><creatorcontrib>Schmidt, Reinhard</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Liver transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klammt, Sebastian</au><au>Mitzner, Steffen R.</au><au>Stange, Jan</au><au>Loock, Jan</au><au>Heemann, Uwe</au><au>Emmrich, Jörg</au><au>Reisinger, Emil C.</au><au>Schmidt, Reinhard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement of impaired albumin binding capacity in acute‐on‐chronic liver failure by albumin dialysis</atitle><jtitle>Liver transplantation</jtitle><addtitle>Liver Transpl</addtitle><date>2008-09</date><risdate>2008</risdate><volume>14</volume><issue>9</issue><spage>1333</spage><epage>1339</epage><pages>1333-1339</pages><issn>1527-6465</issn><eissn>1527-6473</eissn><notes>Telephone: +49 381 494 7515; FAX: +49 381 494 7336</notes><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-News-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><abstract>Extracorporeal albumin dialysis (ECAD) enables the elimination of albumin bound substances and is used as artificial liver support system. Albumin binding function for the benzodiazepine binding site specific marker Dansylsarcosine was estimated in plasma samples of 22 patients with cirrhosis and hyperbilirubinaemia (ECAD: n = 12; control: n = 10) during a period of 30 days in a randomized controlled clinical ECAD trial. Albumin Binding Capacity (ABiC) at baseline was reduced to 31.8% (median; range 24%‐74%) and correlated to the severity of liver disease. Within two weeks a significant improvement of ABiC and a reduction of the albumin bound markers bilirubin and bile acids were observed in the ECAD group. During single treatments a significant decrease of albumin bound substances (bilirubin and bile acids) as well as an increase in ABiC was observed. In the control group, baseline ABiC was significantly lower in patients who died during study period (34.2% vs. 41.7%; P < 0.028), whereas no significant differences were observed for CHILD, coagulation factors, albumin, bile acids nor bilirubin. At baseline 13 patients had a severely impaired ABiC (<40%), improvement of ABiC was more frequent in the ECAD group (5/6) than in the SMT group (2/7). Reduced albumin binding function is present in decompensated liver failure and is related to severity and 30 day survival. ABiC can be improved by ECAD. The beneficial effect of this treatment may be related to the improvement of albumin binding function more than to the elimination of specific substances. Characterization of albumin function by the ABiC test may help to evaluate different liver support systems and other therapeutic measures. Liver Transpl 14:1333–1339,2008. © 2008 AASLD.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>18756471</pmid><doi>10.1002/lt.21504</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1527-6465 |
| ispartof | Liver transplantation, 2008-09, Vol.14 (9), p.1333-1339 |
| issn | 1527-6465 1527-6473 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69496587 |
| source | Wiley Online Library |
| subjects | Adult Albumins - chemistry Albumins - metabolism Benzodiazepines - chemistry Bile Acids and Salts - chemistry Bilirubin - chemistry Binding Sites Dansyl Compounds - chemistry Dialysis - methods Female Fibrosis - metabolism Humans Liver Failure - therapy Male Middle Aged Sarcosine - analogs & derivatives Sarcosine - chemistry Treatment Outcome |
| title | Improvement of impaired albumin binding capacity in acute‐on‐chronic liver failure by albumin dialysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T17%3A50%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20of%20impaired%20albumin%20binding%20capacity%20in%20acute%E2%80%90on%E2%80%90chronic%20liver%20failure%20by%20albumin%20dialysis&rft.jtitle=Liver%20transplantation&rft.au=Klammt,%20Sebastian&rft.date=2008-09&rft.volume=14&rft.issue=9&rft.spage=1333&rft.epage=1339&rft.pages=1333-1339&rft.issn=1527-6465&rft.eissn=1527-6473&rft_id=info:doi/10.1002/lt.21504&rft_dat=%3Cproquest_cross%3E69496587%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3854-9830757422467986a4adfa60093d81ab62d997b21dcb1f8b724bf2fb9547eb243%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69496587&rft_id=info:pmid/18756471&rfr_iscdi=true |